OBJECTIVE: Vitamin D deficiency is associated with increased cardiovascular (CV) disease risk in the general population. We examined the association between vitamin D deficiency and CV risk in rheumatoid arthritis (RA). METHODS: We measured large artery compliance by pulse wave velocity and microvascular function by the reactive hyperemia index in patients with stable RA (n = 87). We quantified CV risk factors, serum 25-hydroxyvitamin D [25(OH)D], and interleukin 17 (IL-17), and RA disease activity by Disease Activity Score of 28 joints. We used linear regression to test associations between serum 25(OH)D and CV risk factors. RESULTS: The mean serum 25(OH)D level in the cohort was 27.1 ± SD 13.6 ng/ml. Fifty-nine patients (68%) were vitamin D-insufficient (25(OH)D < 30 ng/ml; mean 20.2 ± 5.9 ng/ml) and of these, 25 (29%) were vitamin D-deficient (25(OH)D < 20 ng/ml; mean 14.4 ± 3.4 ng/ml). In the whole cohort and the vitamin D-insufficient group, serum 25(OH)D was inversely associated with IL-17 (log IL-17; β = -0.83, p = 0.04; β = -0.63, p = 0.004, respectively) by univariate analysis, which persisted after adjustment for season, and in multivariate analysis after adjustment for confounders (log IL-17; β = -0.74, p = 0.04; β = -0.53, p = 0.02). In vitamin D-deficient patients, serum 25(OH)D was positively associated with microvascular function by univariate and multivariate analysis after adjustment for confounders (β = 2.1, p = 0.04; β = 2.7, p = 0.04). CONCLUSION: Vitamin D deficiency in RA may affect Th17 responses and microvascular function. Maintaining normal serum vitamin D levels may protect against IL-17-mediated inflammation and vascular dysfunction in RA.
OBJECTIVE:Vitamin D deficiency is associated with increased cardiovascular (CV) disease risk in the general population. We examined the association between vitamin D deficiency and CV risk in rheumatoid arthritis (RA). METHODS: We measured large artery compliance by pulse wave velocity and microvascular function by the reactive hyperemia index in patients with stable RA (n = 87). We quantified CV risk factors, serum 25-hydroxyvitamin D [25(OH)D], and interleukin 17 (IL-17), and RA disease activity by Disease Activity Score of 28 joints. We used linear regression to test associations between serum 25(OH)D and CV risk factors. RESULTS: The mean serum 25(OH)D level in the cohort was 27.1 ± SD 13.6 ng/ml. Fifty-nine patients (68%) were vitamin D-insufficient (25(OH)D < 30 ng/ml; mean 20.2 ± 5.9 ng/ml) and of these, 25 (29%) were vitamin D-deficient (25(OH)D < 20 ng/ml; mean 14.4 ± 3.4 ng/ml). In the whole cohort and the vitamin D-insufficient group, serum 25(OH)D was inversely associated with IL-17 (log IL-17; β = -0.83, p = 0.04; β = -0.63, p = 0.004, respectively) by univariate analysis, which persisted after adjustment for season, and in multivariate analysis after adjustment for confounders (log IL-17; β = -0.74, p = 0.04; β = -0.53, p = 0.02). In vitamin D-deficient patients, serum 25(OH)D was positively associated with microvascular function by univariate and multivariate analysis after adjustment for confounders (β = 2.1, p = 0.04; β = 2.7, p = 0.04). CONCLUSION:Vitamin D deficiency in RA may affect Th17 responses and microvascular function. Maintaining normal serum vitamin D levels may protect against IL-17-mediated inflammation and vascular dysfunction in RA.
Entities:
Keywords:
INTERLEUKIN 17; MICROVASCULAR FUNCTION; RHEUMATOID ARTHRITIS; VITAMIN D
Authors: M J L Peters; D P M Symmons; D McCarey; B A C Dijkmans; P Nicola; T K Kvien; I B McInnes; H Haentzschel; M A Gonzalez-Gay; S Provan; A Semb; P Sidiropoulos; G Kitas; Y M Smulders; M Soubrier; Z Szekanecz; N Sattar; M T Nurmohamed Journal: Ann Rheum Dis Date: 2009-09-22 Impact factor: 19.103
Authors: Joshua F Baker; Nehal N Mehta; Daniel G Baker; Gary Toedter; Justine Shults; Joan Marie Von Feldt; Mary B Leonard Journal: Am J Med Date: 2012-07-14 Impact factor: 4.965
Authors: György Kerekes; Pál Soltész; Michael T Nurmohamed; Miguel A Gonzalez-Gay; Maurizio Turiel; Edit Végh; Yehuda Shoenfeld; Iain McInnes; Zoltán Szekanecz Journal: Nat Rev Rheumatol Date: 2012-02-21 Impact factor: 20.543
Authors: Aamer Sandoo; George D Kitas; Douglas Carroll; Jet J C S Veldhuijzen van Zanten Journal: Arthritis Res Ther Date: 2012-05-17 Impact factor: 5.156
Authors: Adam D Gepner; Rekha Ramamurthy; Diane C Krueger; Claudia E Korcarz; Neil Binkley; James H Stein Journal: PLoS One Date: 2012-05-07 Impact factor: 3.240
Authors: Ana Urruticoechea-Arana; María A Martín-Martínez; Santos Castañeda; Carlos A Sanchez Piedra; Carlos González-Juanatey; Javier Llorca; Federico Díaz-Gonzalez; Miguel A González-Gay Journal: Arthritis Res Ther Date: 2015-08-14 Impact factor: 5.156
Authors: Alberto Lo Gullo; Giuseppe Mandraffino; Gianluca Bagnato; Caterina Oriana Aragona; Egidio Imbalzano; Angela D'Ascola; Francesco Rotondo; Antonella Cinquegrani; Enricomaria Mormina; Carlo Saitta; Antonio Giovanni Versace; Maria Adriana Sardo; Renato Lo Gullo; Saverio Loddo; Antonino Saitta Journal: PLoS One Date: 2015-08-04 Impact factor: 3.240